Home - IMMIX BIOPHARMA INC

New Hope for relapsed/refractory AL Amyloidosis ASH Presentation PressRelease Corporate Presentation KOL Event to Discuss ASH 2025 NXC-201 NEXICART-2 Phase 2 Clinical Results Oral Presentation and landscape in relapsed/refractory AL Amyloidosis Hear it From the Media ASCO Post Interview: Shahzad Raza, MD (Cleveland Clinic) Memorial Sloan Kettering: Strong Results for NXC-201 at ASCO Cleveland Clinic:

Keywords

biopharma amyloidosis clinical trials pharmaceutical investors press releases corporate presentations

Tech Stack

Theme:hello-elementor

Plugins:*all-in-one-seo-pack b2i-investor-tools elementor elementor-pro essential-addons-for-elementor-lite happy-elementor-addons url-shortify

Color Palette

Primary#012d47

Accent#ff751f

Background#ededed

Secondary 1#4d4d4d

Secondary 2#e9f5ff

Contact Information

Phone:(310) 651-8041

Social Media:

Bazewp.